🫀 New meta-analysis: NAION and semaglutide—Revisiting the risk

🔥 Key clinical points

• Low absolute rate of non-arteritic anterior ischemic optic neuropathy (NAION) in semaglutide users.
• Observational data for diabetes signal increased NAION hazard (HR 1.85; 95% CI 1.20-2.85); not confirmed in RCTs (RR 1.76; 95% CI 0.43-7.25).
• No increased NAION risk for weight loss populations in RCT and observational data.

🧪 Context:

Systematic review/meta-analysis (8 RCTs, 8 obs. studies; >1.6M patients) stratifying effect by diabetes/obesity, with robust search and data deduplication.

📍 The bottom line:

Absolute NAION risk with semaglutide is low; possible signal in diabetes only from observational data (not corroborated by trial evidence). Maintain routine pharmacovigilance—screen for visual symptoms, but current evidence does not warrant changes in Rx practice.

🔗 Source: PubMed | DOI

📉 Semaglutide lowers CV risk in T2D—oral and subcutaneous forms equally effective

🧪 What was studied

Meta-analysis (4 RCTs, n=19,663) of subcutaneous and oral semaglutide in adults with T2D; endpoints: MACE, MI, stroke, revascularization, HF, mortality.

📈 Key results

• Semaglutide reduced primary MACE (HR 0.83; 95% CI 0.76-0.91)
• Reduced nonfatal MI (HR 0.79) and revascularization (HR 0.71)
• Modest reduction in heart failure hospitalization (HR 0.85)
• No significant difference for CV/all-cause death or stroke compared to control
• No efficacy differences between oral and subcutaneous

📍 What this changes in practice

Both semaglutide formulations robustly lower MACE risk—route of administration may be chosen based on patient preference, SDOH, or tolerability.

🔗 Source: PubMed | Publisher

🩸 Semaglutide and fracture risk: Safer than sleeve gastrectomy?

❓ Clinical question: How does semaglutide compare with sleeve gastrectomy (SG) for fracture risk in obese adults?

✅ Study answer:

Retrospective, propensity-matched cohort (n=2887/group, ~3 yrs follow-up):

• Semaglutide: 2.98% fractures
• SG: 4.43% (HR 0.74, 95% CI 0.56–0.98)
• 26% lower fracture risk in the semaglutide group

📍 How to apply:

Consider semaglutide as a preferred weight loss option in patients at higher baseline fracture risk or with osteoporosis concerns. Continue to assess bone health post weight loss intervention.

🔗 Source: PubMed | DOI

🛡️ Semaglutide & pancreatic β-cell protection: New meta-analysis

🔥 Key findings

• Significant improvement in HOMA-B (insulin secretion index) and reduction in proinsulin:insulin ratio with semaglutide vs. placebo/comparator
• Improved insulin sensitivity (HOMA-IR)
• Certainty of evidence graded “very low” due to study limitations and heterogeneity

🧪 Context

Systematic review/meta-analysis (16 RCTs, n=6591 adults with T2D); primary endpoints centered on β-cell function.

📍 Practical value

Semaglutide likely improves β-cell function and insulin resistance, which could explain durable glucose lowering—though the evidence is still uncertain. Individualize decision-making; further data needed for definitive guidance.

🔗 Source: PubMed | DOI

⚠️ Safety alert: Transient intestinal ischemia after Wegovy

🧪 Context

Single case report: middle-aged man developed transient intestinal ischemia after first Wegovy (semaglutide) dose for obesity; event is extremely rare.

📊 Numbers:

Only one prior similar report exists.

📍 Actions:

Educate patients regarding warning signs of severe abdominal pain at treatment initiation. Promptly investigate gastrointestinal “ischemic” symptoms in patients on semaglutide.

🔗 Source: PubMed | DOI

✅ Biliary safety win: GLP-1/GIP agonists cut gallstone complications in T2D + IBD

❓ Practice question: Do GLP-1-based agents (semaglutide/tirzepatide) increase gallstone-related events in high-risk diabetes/IBD patients?

✅ Study answer:

Real-world, propensity-matched cohort (n=32,052): lower rates of cholelithiasis (3.5% vs 6.3%), cholecystitis, and choledocholithiasis for GLP-1/GIP users vs non-users. No difference for cholangitis.

📍 How to apply:

Reassure high-risk (T2D+IBD) patients that biliary complications are not increased—and may in fact be reduced—with GLP-1/GIP therapy; continue usual gallbladder monitoring.

🔗 Source: PubMed | DOI

🧠 Review: GLP-1 agonists in neurodegenerative disease—early clues but clinical benefit unproven

🧪 What was studied

Narrative reviews (see also PMID 41465588) summarize preclinical mechanisms and clinical trial results for semaglutide and other GLP-1RAs in Parkinson’s and Alzheimer’s.

📈 Key results

• GLP-1RAs modulate neuroinflammation, mitochondrial dysfunction, proteostasis, and synaptic resilience.
• Clinical studies in AD: improved brain glucose metabolism, but not cognitive outcomes.
• In PD: modest early improvement in motor/non-motor symptoms, no proven disease modification to date.

📍 What this changes in practice

Promising, but do not currently recommend GLP-1RAs solely for neurodegeneration—limit to evidence-based indications unless in clinical trials.

🔗 Sources:

PMID 41465832 | DOI

PMID 41465588 | DOI

👥 Sex differences: SC beats oral semaglutide—distinct benefits for men and women

🔥 Main in 3 points:

• Subcutaneous (SC) semaglutide outperforms oral for glycaemic and weight control in men.
• Women on SC semaglutide have larger benefit on liver health (steatosis index, GOT).
• Both forms effective, but effect size varies by sex and outcome.

🧪 Context:

12-month, real-world comparative effectiveness study (n=208 T2D; oral vs. SC semaglutide, sex-stratified endpoints).

📍 Practical significance:

For men prioritizing metabolic endpoints (HbA1c, weight), SC semaglutide may be favored. For women with steatosis/liver risk, consider added benefit of SC route.

🔗 Source: PubMed | DOI

🩺 Semaglutide and cardiovascular/renal benefit in CKD

🧪 What was studied

Narrative review of RCTs/RWE for semaglutide in T2D and CKD, highlighting the Evaluate Renal Function with Semaglutide Once Weekly and inclusion in contemporary KDIGO guidelines.

📈 Key results

• Reduces kidney failure, CV death, major CV events, and albuminuria in T2D/CKD.
• Now considered the “fourth pillar” in DKD therapy (after SGLT2i, MRA, RAAS blockers).
• Metabolic benefit extends to non-diabetic CKD but data less robust.

📍 What this changes in practice

Initiate semaglutide earlier in T2D/CKD alongside other renoprotective agents; individualize for metabolic targets unattainable with other therapies.

🔗 Source: PubMed | DOI